发明公开
- 专利标题： PYRROLIDINE ETHER DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
- 专利标题（中）： 作为NK3受体拮抗剂的吡咯烷衍生物
-
申请号： EP09761673.4申请日： 2009-06-08
-
公开(公告)号： EP2294063A1公开(公告)日： 2011-03-16
- 发明人: JABLONSKI, Philippe , KAWASAKI, Kenichi , KNUST, Henner , LIMBERG, Anja , NETTEKOVEN, Matthias , RATNI, Hasane , RIEMER, Claus
- 申请人： F. Hoffmann-La Roche AG
- 申请人地址： Grenzacherstrasse 124 4070 Basel CH
- 专利权人： F. Hoffmann-La Roche AG
- 当前专利权人： F. Hoffmann-La Roche AG
- 当前专利权人地址： Grenzacherstrasse 124 4070 Basel CH
- 代理机构： Poppe, Regina
- 优先权： EP08157952 20080610
- 国际公布： WO2009150110 20091217
- 主分类号： C07D401/12
- IPC分类号： C07D401/12 ; C07D401/14 ; A61K31/445 ; A61P25/00
摘要：
The present invention relates to a compounds of formula I wherein R
1 , R
2 , R
3 , R', Ar, o, n and m are as defined in the specification. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
1 , R
2 , R
3 , R', Ar, o, n and m are as defined in the specification. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
公开/授权文献
- EP2294063B1 PYRROLIDINE ETHER DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS 公开/授权日：2011-11-02
信息查询
